NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, A, R4, n, and R7 are as defined in the specification. Corresponding pharmaceutical compositions, methods...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	SCOT R. MENTE, TODD W. BUTLER, CHAKRAPANI SUBRAMANYAM, RAMALAKSHMI Y. CHANDRASEKARAN, TRAVIS T. WAGNER
Format:	Patent
Sprache:	eng ; spa
Schlagworte:	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, A, R4, n, and R7 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed. Se describen compuestos y sales de estos aceptables desde el punto de vista farmacéutico, en donde los compuestos tienen la estructura de la Fórmula I: (Ver Formula) y sales de estos aceptables desde el punto de vista farmacéutico, en donde X, Y, A, R4, n y R7 son como se definen en la memoria descriptiva. También se describen composiciones farmacéuticas, métodos de tratamiento, métodos de síntesis e intermediarios correspondientes.